Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases.
Patients with neoplastic diseases are predisposed to develop invasive fungal infections as the result of impairments of host defense mechanisms due principally to pharmacologic immunosuppression resulting from intensive cytotoxic chemotherapy, ablative radiation therapy, and corticosteroids. Candida species, Aspergillus species, and emerging opportunistic fungal pathogens comprise the principal etiologic agents of opportunistic mycoses in cancer patients. This paper reviews the recent progress, particularly during the year of 1991, in management of invasive fungal infections and the current problems of invasive mycosis, which confront patients with neoplastic diseases.
Walsh
T J
TJ
National Cancer Institute, Bethesda, Maryland.
Lee
J W
JW
Roilides
E
E
Pizzo
P A
PA
D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D002177:Candidiasis / Q000188:drug therapy / Q000209:etiology; D016207:Cytokines / Q000627:therapeutic use; D004198:Disease Susceptibility / Q000209:etiology; D016469:Fungemia / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000935:Antifungal Agents; D016207:Cytokines; D007155:Immunologic Factors; D011994:Recombinant Proteins